JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

B3272 Inauhzin

Target: Sir2-like Family Deacetylases (Sirtuins)

Summary: SIRT1 inhibitor

≥23.5 mg/mL
A3012 Ruxolitinib (INCB018424)
4 Citation

Target: JAK

Summary: JAK inhibitor

insoluble in H2O; ≥15.32 mg/mL
A4083 Rocilinostat (ACY-1215)
1 Citation

Target: Histone Deacetylases (HDACs)

Summary: Selective HDAC6 inhibitor

≥21.675 mg/mL
A4084 Vorinostat (SAHA, MK0683)
9 Citation

Target: Histone Deacetylases (HDACs)

Summary: HDAC inhibitor

insoluble in EtOH; insoluble in H2O; ≥4.41 mg/mL
A4089 Mocetinostat (MGCD0103, MG0103)
2 Citation

Target: Histone Deacetylases (HDACs)

Summary: HDAC inhibitor,isotype-selective and potent

insoluble in EtOH; insoluble in H2O; ≥19.8 mg/mL
A4090 JNJ-26481585
3 Citation

Target: Histone Deacetylases (HDACs)

Summary: Potent HDAC inhibitor

insoluble in H2O; insoluble in EtOH; ≥19.2 mg/mL
A4092 CUDC-101
1 Citation

Target: Histone Deacetylases (HDACs)|EGFR|ErbB

Summary: Multitargeted HDAC inhibitor

≥21.7 mg/mL
A4137 AZD1480

Target: JAK

Summary: JAK2 inhibitor,ATP-competitive and novel

insoluble in H2O; ≥93.8 mg/mL
A4140 WP1066

Target: STAT|JAK

Summary: JAK2/STAT3 inhibitor,cell-permeable

insoluble in H2O; ≥17.8 mg/mL
A4147 LY2784544

Target: Aurora Kinases|FLT3|VEGFR|FGFR|Trk Receptors|JAK|ALK|TYK2|MUSK|MAP3K

Summary: JAK2 inhibitor,highly potent and selective

≥23.5 mg/mL